WISE Raises $34.8M Series D
Summary
WISE is a Milan-based neurotechnology company developing stretchable electronic circuits and soft implantable electrodes for neural interfacing, including its FDA-cleared Wise Cortical Strip and the Heron lead for spinal cord stimulation. It closed an oversubscribed Series D of approximately $34.8 million (€30 million) with participation from Wallaby S.p.A, New Frontier, Eureka Venture, Indaco Ventures and ENEA Tech. Capital will advance the Heron SCS lead through regulatory pathways, a first-in-human study and commercial scale-up of its electrode portfolio.
Why it matters
WISE's €30M Series D funds the first-in-human study of Heron, a lead that combines the precision of surgical paddle leads with the lower procedural burden of percutaneous implantation. The round signals continued investor confidence in Europe's spinal cord stimulation market even as the company expands into BCI applications.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial